Form 4 for AMGN Amgen

Accepted 2024-03-20 00:00:00 ET · period of report 2024-03-18 · accession 0001127602-24-010852 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2024-03-20	2024-03-18	AMGN	Griffith Peter H.	EVP, CFO	F - Tax	$268.87	-5,168	34.7K	-13%	-$1.39M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-03-18	F	D	5,168	$268.87	34,710	D	—	—	(F1) These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,151 RSUs which will vest on 5/5/2024; 2,237 RSUs which will vest in installments of 1,102 on 4/30/2024 and 1,135 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 each on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026 and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 448 shares acquired, beginning on March 8, 2022 in amounts ranging between approximately 30 and 127 shares on the Company's quarterly dividend payout dates pursuant to a broker-administered DRIP meeting the requirements of Rule 16a-11. (F3) These shares include 779 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.